Earnings Ahead

MRK - Merck

100.89 -1.38 -1.35

Merck

Merck

About

Profile

Our corporate responsibility approach is aligned with our company’s focus on invention, and underscores our commitment to overcoming the greatest obstacles to health and well-being, developing and rewarding our employees, protecting the environment, and


Headquarters

Kenilworth, New Jersey, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

MRK



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Susan Monarez wins Senate confirmation as CDC director
  • FDA vaccines head, chief medical officer Vinay Prasad departs agency
  • Merck outlines $3B reinvestment initiative and expects 1%–2% revenue growth for 2025 while advancing new product launches
  • EU pharma lobby criticizes potential Trump tariffs on pharmaceuticals
  • Biggest stock movers Tuesday: SOFI, UNH, TLRY, PHG, and more
  • Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2
  • Merck plans $3B annual cost cuts as Keytruda faces patent cliff
  • Merck Non-GAAP EPS of $2.13 beats by $0.10, revenue of $15.81B misses by $60M
  • RFK Jr. seeks to 'fix' Vaccine Injury Compensation Program
  • Merck Q2 Earnings Preview: What to expect?
  • Merck declares $0.81 dividend
  • Former biotech exec George Tidmarsh to lead key FDA drug center
  • Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
  • Trump eyes drug, chip tariffs by month-end
  • Merck to begin late-stage trials for HIV prevention pill
  • Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more
  • FDA mulls faster drug reviews in exchange for lower prices in U.S.- Bloomberg
  • Merck Animal Health gets FDA nod for Bravecto Quantum
  • FDA publishes more than 200 rejection letters in a bid to improve transparency
  • Merck's doravirine/islatravir under FDA review for HIV

Earnings History

Date EPS / Forecast Revenue / Forecast
February 3, 2022 1.8 / 1.52 13.52B / 13.14B Beat!
October 28, 2021 1.75 / 1.55 13.15B / 12.32B Beat!
July 29, 2021 1.31 / 1.31 11.4B / 11.08B Beat!
April 29, 2021 1.33 / 1.53 12.08B / 12.61B
February 4, 2021 1.32 / 1.38 12.51B / 12.67B
October 27, 2020 1.74 / 1.44 12.55B / 12.21B Beat!
July 31, 2020 1.37 / 1.06 10.87B / 10.4B Beat!
April 28, 2020 1.5 / 1.34 12.06B / 11.48B Beat!
February 5, 2020 1.16 / 1.15 11.87B / 11.98B
October 29, 2019 1.51 / 1.24 12.4B / 11.64B Beat!
July 30, 2019 1.3 / 1.16 11.76B / 10.96B Beat!
April 30, 2019 1.22 / 1.05 10.82B / 10.47B Beat!
February 1, 2019 1.04 / 1.04 11B / 10.94B Beat!
October 25, 2018 1.19 / 1.14 10.79B / 10.89B
July 27, 2018 1.06 / 1.03 10.47B / 10.28B Beat!
May 1, 2018 1.05 / 1 10.04B / 10.09B
February 2, 2018 0.98 / 0.94 10.43B / 10,494M
October 27, 2017 1.11 / 1.03 10.33B / 10,545M
July 28, 2017 1.01 / 0.87 9.93B / 9,746M Beat!
May 2, 2017 0.88 / 0.83 9.43B / 9,250M Beat!
Date Price Open High Low Vol Change
Dec 4 100.89 102.1
102.12
100.55
12.4M -1.35%
Dec 3 102.27 101.9
103.09
101.52
12.5M 1.23%
Dec 2 101.03 101.53
101.8
100.31
11.8M -0.79%
Dec 1 101.83 104.72
105.68
101.71
14.2M -2.86%
Nov 28 104.83 104.83
105.4
104.12
6.2M 0.19%
 
Nov 26 104.63 104.6
105.75
104.2
12.6M -0.97%
Nov 25 105.66 100.73
105.84
100.71
22.2M 5.24%
Nov 24 100.4 99.12
102.36
99.12
28.3M 2.70%
Nov 21 97.76 95.48
100.27
95.36
23.2M 2.94%
Nov 20 94.97 94.97
96
93.9
12.6M -0.08%
Nov 19 95.05 96
97.14
94.09
14.6M -1.43%
Nov 18 96.43 94.11
97.66
92.11
28.2M 3.84%
Nov 17 92.86 93.23
94.75
92.68
14.3M -0.06%
Nov 14 92.92 92.2
95.07
91.49
19.6M -0.01%
Nov 13 92.93 91.31
94.26
90.9
16.1M 1.62%
Nov 12 91.45 91.41
92.91
91.16
13.2M 0.55%
Nov 11 90.95 87.35
91.07
87.26
15.4M 4.84%
Nov 10 86.75 86.69
87.37
85.8
8.3M 0.54%
Nov 7 86.28 85.95
86.58
85.24
9.2M 0.58%
Nov 6 85.78 84.48
86.17
84.35
10.6M 1.65%
Nov 5 84.39 84.03
85.38
82.91
9.4M 0.63%
Nov 4 83.86 82.7
84.96
82.01
12.8M 1.66%
Nov 3 82.49 85.76
86.1
82.34
13.9M -4.06%
Oct 31 85.98 85.42
86.46
84.56
12.4M -0.35%
Oct 30 86.28 84.62
87.3
83.3
16.7M -0.35%
Oct 29 86.58 86.94
87.84
86.07
10.9M -0.52%
Oct 28 87.03 88.11
88.11
86.93
8.3M -1.1%
Oct 27 88 87.51
88.29
87.03
7.2M 0.58%
Oct 24 87.49 87.33
88.06
87.11
7.9M 0.36%
Oct 23 87.18 87.56
88.11
86.91
7.7M -0.49%
Oct 22 87.61 87.68
88.79
87.01
10.9M -0.01%
Oct 21 87.62 86.96
87.67
86.23
9.9M 1.51%
Oct 20 86.32 85.25
87
85.03
8.6M 1.80%
Oct 17 84.79 83.28
84.89
83.16
10.8M 1.04%
Oct 16 83.92 84.41
85.5
83.6
11.7M -0.23%
Oct 15 84.11 84.19
84.69
83.61
9.2M -0.7%
Oct 14 84.7 85.38
85.68
84.15
9.7M -1.17%
Oct 13 85.7 85.65
86.46
85.24
6.6M -0.34%
Oct 10 85.99 87.93
88.24
85.92
11.2M -1.73%
Oct 9 87.5 86.96
87.8
86.64
10.9M 1.27%
Oct 8 86.4 87.93
87.93
86.2
9.7M -1.38%
Oct 7 87.61 88.67
88.94
87.14
9.4M -1.34%
Oct 6 88.8 88.83
90.31
88.55
11.6M -0.44%
Oct 3 89.19 89.63
90.7
88.1
13.0M -0.36%
Oct 2 89.51 89.95
91
88.22
14.6M -0.69%
Oct 1 90.13 85.19
90.75
85.19
33.5M 7.39%
Sep 30 83.93 78.42
84
78.39
21.6M 6.81%
Sep 29 78.58 78.6
78.8
78.03
12.7M 0.03%
Sep 26 78.56 78.76
78.96
77.69
12.2M 1.24%
Sep 25 77.6 79.78
79.88
77.58
14.9M -2.6%
Sep 24 79.67 79.9
80.11
79.33
11.8M -0.36%
Sep 23 79.96 80.09
81.11
79.67
13.1M -0.55%
Sep 22 80.4 81.76
81.94
80.26
12.0M -1.36%
Sep 19 81.51 81.81
82.4
81
25.6M -0.02%
Sep 18 81.53 81.22
81.68
80.82
10.5M 0.48%
Sep 17 81.14 80.98
82.25
80.8
12.6M 0.06%
Sep 16 81.09 81.01
81.48
80.54
10.1M 0.09%
Sep 15 81.02 82.11
82.75
80.92
10.2M -2.16%
Sep 12 82.81 84.62
85.18
82.8
9.9M -2.75%
Sep 11 85.15 84.34
85.55
84
9.7M 0%